These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 38447887

  • 1. The impact of induction therapy on the risk of posttransplant lymphoproliferative disorder in adult kidney transplant recipients with donor-recipient serological Epstein-Barr virus mismatch.
    Attieh RM, Wadei HM, Mao MA, Mao SA, Pungpapong S, Taner CB, Jarmi T, Cheungpasitporn W, Leeaphorn N.
    Am J Transplant; 2024 Aug; 24(8):1486-1494. PubMed ID: 38447887
    [Abstract] [Full Text] [Related]

  • 2. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV.
    Nephrol Dial Transplant; 2012 Jul; 27(7):2971-9. PubMed ID: 22273720
    [Abstract] [Full Text] [Related]

  • 3. Posttransplant Lymphoproliferative Disorders in Epstein-Barr Virus Donor Positive/Recipient Negative Lung Transplant Recipients.
    Courtwright AM, Burkett P, Divo M, Keller S, Rosas IO, Trindade A, Mody GN, Singh SK, El-Chemaly S, Camp PC, Goldberg HJ, Mallidi HR.
    Ann Thorac Surg; 2018 Feb; 105(2):441-447. PubMed ID: 29223419
    [Abstract] [Full Text] [Related]

  • 4. Induction regimens and post-transplantation lymphoproliferative disorder after pediatric intestinal transplantation: Single-center experience.
    Devine K, Ranganathan S, Mazariegos G, Bond G, Soltys K, Ganoza A, Sun Q, Sindhi R.
    Pediatr Transplant; 2020 Aug; 24(5):e13723. PubMed ID: 32424963
    [Abstract] [Full Text] [Related]

  • 5. Belatacept for kidney transplant recipients.
    Masson P, Henderson L, Chapman JR, Craig JC, Webster AC.
    Cochrane Database Syst Rev; 2014 Nov 24; 2014(11):CD010699. PubMed ID: 25416857
    [Abstract] [Full Text] [Related]

  • 6. Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation.
    Kalra A, Roessner C, Jupp J, Williamson T, Tellier R, Chaudhry A, Khan F, Taparia M, Jimenez-Zepeda VH, Stewart DA, Daly A, Storek J.
    Clin Transplant; 2018 Jan 24; 32(1):. PubMed ID: 29114932
    [Abstract] [Full Text] [Related]

  • 7. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases.
    Nash RA, Dansey R, Storek J, Georges GE, Bowen JD, Holmberg LA, Kraft GH, Mayes MD, McDonagh KT, Chen CS, Dipersio J, Lemaistre CF, Pavletic S, Sullivan KM, Sunderhaus J, Furst DE, McSweeney PA.
    Biol Blood Marrow Transplant; 2003 Sep 24; 9(9):583-91. PubMed ID: 14506660
    [Abstract] [Full Text] [Related]

  • 8. Incidence, Risk Factors, Clinical Management, and Outcomes of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients.
    Liu M, Husain S, Famure O, Li Y, Kim SJ.
    Prog Transplant; 2019 Jun 24; 29(2):185-193. PubMed ID: 30845885
    [Abstract] [Full Text] [Related]

  • 9. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV.
    Transplantation; 2012 Jan 15; 93(1):73-81. PubMed ID: 22129761
    [Abstract] [Full Text] [Related]

  • 10. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
    Hosseini-Moghaddam SM, Alhomayeed B, Soliman N, Weir MA, House AA.
    Transpl Infect Dis; 2016 Jun 15; 18(3):423-30. PubMed ID: 27016725
    [Abstract] [Full Text] [Related]

  • 11. Idiopathic pulmonary fibrosis lung transplant recipients are at increased risk for EBV-associated posttransplant lymphoproliferative disorder and worse survival.
    Iasella CJ, Winters SA, Kois A, Cho J, Hannan SJ, Koshy R, Moore CA, Ensor CR, Lendermon EA, Morrell MR, Pilewski JM, Sanchez PG, Kass DJ, Alder JK, Nouraie SM, McDyer JF.
    Am J Transplant; 2020 May 15; 20(5):1439-1446. PubMed ID: 31874120
    [Abstract] [Full Text] [Related]

  • 12. Steroid maintenance in repeat kidney transplantation: influence of induction agents on outcomes.
    Sureshkumar KK, Hussain SM, Nashar K, Marcus RJ.
    Saudi J Kidney Dis Transpl; 2014 Jul 15; 25(4):741-9. PubMed ID: 24969182
    [Abstract] [Full Text] [Related]

  • 13. Epstein-Barr virus infection in adult renal transplant recipients.
    Morton M, Coupes B, Roberts SA, Johnson SL, Klapper PE, Vallely PJ, Picton ML.
    Am J Transplant; 2014 Jul 15; 14(7):1619-29. PubMed ID: 24815922
    [Abstract] [Full Text] [Related]

  • 14. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P.
    J Heart Lung Transplant; 2008 Jan 15; 27(1):100-5. PubMed ID: 18187094
    [Abstract] [Full Text] [Related]

  • 15. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients.
    Smith JM, Corey L, Healey PJ, Davis CL, McDonald RA.
    Transplantation; 2007 Jun 15; 83(11):1423-8. PubMed ID: 17565314
    [Abstract] [Full Text] [Related]

  • 16. Clinical and virologic outcomes in high-risk adult Epstein-Barr virus mismatched organ transplant recipients.
    Kumar D, Patil N, Husain S, Chaparro C, Bhat M, Kim SJ, Humar A.
    Clin Transplant; 2017 Jul 15; 31(7):. PubMed ID: 28489256
    [Abstract] [Full Text] [Related]

  • 17. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
    Gao XN, Lin J, Wang LJ, Li F, Li HH, Wang SH, Huang WR, Gao CJ, Yu L, Liu DH.
    Ann Hematol; 2019 Sep 15; 98(9):2163-2177. PubMed ID: 31243569
    [Abstract] [Full Text] [Related]

  • 18. EBV-PTLD, Adenovirus, and CMV in Pediatric Allogeneic Transplants With Alemtuzumab as Part of Pretransplant Conditioning: A Retrospective Single Center Study.
    Cupit-Link MC, Nageswara Rao A, Warad DM, Rodriguez V, Khan S.
    J Pediatr Hematol Oncol; 2018 Nov 15; 40(8):e473-e478. PubMed ID: 29620685
    [Abstract] [Full Text] [Related]

  • 19. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
    Patel C, Pasciolla M, Abramova R, Salerno D, Gomez-Arteaga A, Shore TB, Orfali N, Mayer S, Hsu J, Phillips AA, Chaekal OK, Satlin MJ, Soave R, Kodiyanplakkal RPL, Drelick A, Plate M, Besien KV.
    Transplant Cell Ther; 2023 Feb 15; 29(2):132.e1-132.e5. PubMed ID: 36334653
    [Abstract] [Full Text] [Related]

  • 20. Lymphoproliferative disorders after renal transplantation along 2 decades: a large longitudinal study of 21.546 recipients.
    Franco A, Hernandez D, Zarraga S, Fructuoso AS, Crespo M, Mazuecos A, Corte CD, Benot AR, Ruiz JC, Beneyto I, en representación del grupo GREAT.
    Nefrologia (Engl Ed); 2023 Feb 15; 43(4):427-434. PubMed ID: 37813738
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.